Kintor Pharmaceuticals has announced positive topline results from the Phase III stage of its pivotal trial for pyrilutamide (KX-826) tincture 1.0%, a potential first-in-class topical treatment for male androgenetic alopecia (AGA) in China. The study met its primary efficacy endpoint, with both the 1.0% and 0.5% twice-daily formulations demonstrating statistically significant and clinically meaningful improvements in target area hair count compared to a placebo. The 1.0% dose increased hair count by 10.65 hairs/cm² more than the placebo.

The therapy showed an excellent safety and tolerability profile, with no drug-related serious adverse events reported and an incidence of adverse events similar to the placebo group. Pyrilutamide is a topical antiandrogen that works by locally blocking the androgen receptor. Kintor plans to submit a new drug application for the 1.0% formulation in the near future, marking a significant step towards providing a new non-systemic treatment option for male pattern hair loss in China.

PharmCube's NextBiopharm® database shows that Kintor is also developing pyrilutamide for acne. Click here to request a free trial for NextBiopharm®.